Molecular & Cellular Oncology

SCIE

国际简称：MOL CELL ONCOL 参考译名：分子与细胞肿瘤学

主要研究方向：ONCOLOGY 非预警期刊审稿周期：6 Weeks

《分子与细胞肿瘤学》(Molecular & Cellular Oncology)是一本由Taylor & Francis出版的以ONCOLOGY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q3 JCR分区
10 年发文量
2.1 IF影响因子
未开放 是否OA
6 issues/year 出版周期
English 出版语言

Molecular&Cellular Oncology is an international academic journal dedicated to cancer research, publishing research articles related to the molecular and cellular mechanisms of cancer. This journal aims to promote a deeper understanding of cancer occurrence, development, and treatment, and explore new diagnostic methods and treatment strategies. As a part of the medical field, it particularly focuses on the application of molecular biology and cell biology in cancer research.

Magazines play an important role in the field of cancer research as they provide a platform specifically for discussing molecular and cellular level research on cancer. The characteristic of the journal is that it encourages interdisciplinary research, including the combination of basic science and clinical research, as well as the exploration of new anti-cancer therapies. In addition, the journal's fast publication speed and commitment to high-quality research make it one of the preferred journals for cancer researchers.

[ 查看全部 ]

投稿咨询加急咨询

Molecular & Cellular Oncology期刊信息

ISSN：2372-3556
出版语言：English
是否OA：未开放
出版地区：United Kingdom
是否预警：否
出版商：Taylor & Francis
出版周期：6 issues/year
开源占比：0.4958
Gold OA文章占比：100.00%
OA被引用占比：0.2656...
出版国人文章占比：0
出版撤稿占比：
研究类文章占比：90.00%

Molecular & Cellular Oncology CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

0.62

0.398

学科类别	分区	排名	百分位
大类：Biochemistry, Genetics and Molecular Biology 小类：Cancer Research	Q4	178 / 233	23%
大类：Biochemistry, Genetics and Molecular Biology 小类：Molecular Medicine	Q4	140 / 179	22%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Molecular & Cellular Oncology中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

Molecular & Cellular Oncology JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	ESCI	Q3	236 / 333	29.3
学科：ONCOLOGY	ESCI	Q4	260 / 333	22.07

Molecular & Cellular Oncology历年数据统计

影响因子

中科院分区

Molecular & Cellular Oncology中国学者发文选摘

1、Exploration of the diagnostic and therapeutic potential of the nucleocytoplasmic shuttling protein TMUB1 by inducing G0/G1 cell cycle arrest in ovarian cance
Author: Jiang, Jiahong; Li, Jie; Tang, Shuai; Shu, Liping; Chen, Yanhong; Qian, Jiaxian; Wang, Yanzhou; Chen, Yin

Journal: MOLECULAR & CELLULAR ONCOLOGY. 2026; Vol. 13, Issue 1, pp. -. DOI: 10.1080/23723556.2026.2650223
2、Lactylation-related genes signature panel in hepatocellular carcinoma reveals the prognostic and therapeutic optimizatio
Author: Xiao, Ting; Xu, Xianqun; Zhao, Ziwu; Xue, Han; Guo, Shuang; Long, Xinghua

Journal: MOLECULAR & CELLULAR ONCOLOGY. 2026; Vol. 13, Issue 1, pp. -. DOI: 10.1080/23723556.2026.2621475
3、SNX1 inhibits human ovarian cancer progression via regulation of the cell cycle, apoptosis and migratio
Author: Li, Pin; Yu, Xiaoyan; Wen, Kailing; Wang, Lei; Yu, Jingran; Chen, Ping

Journal: MOLECULAR & CELLULAR ONCOLOGY. 2026; Vol. 13, Issue 1, pp. -. DOI: 10.1080/23723556.2025.2604899
4、TRIM22 promotes glioblastoma development by ubiquitinating Bcl-
Author: Zhang, Jiahao; Chen, Yuning; Wang, Gaosong; Huang, Hui; Liu, Yuankun; Huang, Jin; Shao, Junfei; Jiao, Jiantong; Cheng, Chao

Journal: MOLECULAR & CELLULAR ONCOLOGY. 2025; Vol. 12, Issue 1, pp. -. DOI: 10.1080/23723556.2025.2518679
5、Single-cell analysis reveals XCL1+ CD8+ T cells as a therapeutic target in hepatocellular carcinom
Author: Li, Guowei; Yang, Fan; Li, Zechao; Chen, Zhicheng; Luo, Geng; Yuan, Hongtao; Zhao, Chaoxian

Journal: MOLECULAR & CELLULAR ONCOLOGY. 2025; Vol. 12, Issue 1, pp. -. DOI: 10.1080/23723556.2025.2523085
6、CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A54
Author: Ke, Zhi-Yin; Fu, Tian; Wang, Xue-Chun; Ma, Xuan; Yin, Hai-Han; Wang, Wen-Xuan; Liu, Yong-Jun; Liang, Ai-Ling

Journal: MOLECULAR & CELLULAR ONCOLOGY. 2025; Vol. 12, Issue 1, pp. -. DOI: 10.1080/23723556.2025.2488537